Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Gils

Showing results (51-60 of 162) with videos related to

Pageof 17
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|December 13, 2005
Development of ELISAs measuring the extent of TAFI activationErik Ceresa, Els Brouwers, Miet Peeters, et al.
Blood|February 24, 2011
Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism modelEllen Vercauteren, Jan Emmerechts, Miet Peeters, et al.
British Journal of Clinical Pharmacology|May 17, 2020
Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's diseaseErwin Dreesen, Sophie Berends, David Laharie, et al.
Journal of Gastroenterology and Hepatology|December 28, 2018
Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patientsNathalie Van den Berghe, Bram Verstockt, Sophie Tops, et al.
Inflammatory Bowel Diseases|March 9, 2016
Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical SamplesAnn Gils, Thomas Van Stappen, Erwin Dreesen, et al.
Drug Testing and Analysis|July 26, 2017
Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn's diseaseSumin Bian, Jiadi Lu, Filip Delport, et al.
United European Gastroenterology Journal|July 19, 2019
Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseasesClaire Liefferinckx, Bram Verstockt, Ann Gils, et al.
Biosensors & Bioelectronics|December 29, 2015
Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patientsJiadi Lu, Thomas Van Stappen, Dragana Spasic, et al.
Gut|April 29, 2017
Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trialThomas Van Stappen, Niels Vande Casteele, Gert Van Assche, et al.
British Journal of Clinical Pharmacology|January 12, 2019
Optimising infliximab induction dosing for patients with ulcerative colitisErwin Dreesen, Ruben Faelens, Gert Van Assche, et al.
Pageof 17

Showing results (51-60 of 162) with videos related to

Sort By:
Pageof 17
Arteriosclerosis, Thrombosis, and Vascular Biology|December 13, 2005
Development of ELISAs measuring the extent of TAFI activationErik Ceresa, Els Brouwers, Miet Peeters, et al.
Blood|February 24, 2011
Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism modelEllen Vercauteren, Jan Emmerechts, Miet Peeters, et al.
British Journal of Clinical Pharmacology|May 17, 2020
Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's diseaseErwin Dreesen, Sophie Berends, David Laharie, et al.
Journal of Gastroenterology and Hepatology|December 28, 2018
Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patientsNathalie Van den Berghe, Bram Verstockt, Sophie Tops, et al.
Inflammatory Bowel Diseases|March 9, 2016
Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical SamplesAnn Gils, Thomas Van Stappen, Erwin Dreesen, et al.
Drug Testing and Analysis|July 26, 2017
Development and validation of an optical biosensor for rapid monitoring of adalimumab in serum of patients with Crohn's diseaseSumin Bian, Jiadi Lu, Filip Delport, et al.
United European Gastroenterology Journal|July 19, 2019
Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseasesClaire Liefferinckx, Bram Verstockt, Ann Gils, et al.
Biosensors & Bioelectronics|December 29, 2015
Fiber optic-SPR platform for fast and sensitive infliximab detection in serum of inflammatory bowel disease patientsJiadi Lu, Thomas Van Stappen, Dragana Spasic, et al.
Gut|April 29, 2017
Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trialThomas Van Stappen, Niels Vande Casteele, Gert Van Assche, et al.
British Journal of Clinical Pharmacology|January 12, 2019
Optimising infliximab induction dosing for patients with ulcerative colitisErwin Dreesen, Ruben Faelens, Gert Van Assche, et al.
Pageof 17